Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04563767 · ClinicalTrials.gov registry record
Feasibility - Infinitome
A clinical trial of Alzheimer Disease, sponsored by HealthPartners Institute.
- Completed
- Registry status
- 4
- Enrollment target
- 1
- Study location
NCT04563767: Completed study of Alzheimer Disease, sponsored by HealthPartners Institute.
NCT04563767 is a study of Alzheimer Disease that has completed, run by HealthPartners Institute. The registered enrollment target is 4 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04563767, a study of Alzheimer Disease, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The Infinitome Program from Omniscient has the ability to identify abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI). This technology, which visualizes brain networks in three dimensions, was originally developed to ensure neurosurgeons avoid inadvertently lesioning cognitively eloquent brain regions during surgical operations. The potential of Infinitome in identifying connectome dysfunction for neurodegenerative diseases such as Alzheimer's disease has yet to be explored. This diagnostic technique may play a critical role for identifying disease brain networks that may benefit from targeted interventions in clinical trials.
Primary Outcome
Percent of subjects who complete the sequence of the fMRI protocol. Range: 0-100. Higher percentage indicates more completion.
Conditions Studied
Interventions
- PROCEDURE Infinitome
Study Locations (1)
Minnesota
- HealthPartners Neuroscience Center - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-09-15 |
| Est. Completion | 2020-10-13 |
What the finished NCT04563767 record still lists
NCT04563767 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Infinitome is the first listed.
NCT04563767 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04563767 about?
NCT04563767 is a clinical study titled "Feasibility - Infinitome". The Infinitome Program from Omniscient has the ability to identify abnormal brain networks or connectomes using resting state functional MRI (rs-fMRI). This technology, which visualizes brain networks in three dimensions, was originally developed to ensure neurosurgeons avoid inadvertently lesioning...
What is the current status of trial NCT04563767?
This trial is currently completed. The enrollment target is 4 participants. The study started on 2020-09-15. Estimated completion is 2020-10-13.
What conditions does trial NCT04563767 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT04563767?
The interventions under investigation include: Infinitome (PROCEDURE).
Who is sponsoring clinical trial NCT04563767?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04563767 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04563767's enrollment target sits among peer trials
4 303rd of 306 higher than 3 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI